IRIS - Res&Arch Institutional Research Information System - Research & Archive

CRINO', Lucio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.736
EU - Europa 2.792
AS - Asia 2.400
SA - Sud America 461
AF - Africa 50
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 9.441
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.659
SG - Singapore 1.120
IE - Irlanda 598
IT - Italia 403
BR - Brasile 401
SE - Svezia 394
CN - Cina 371
RU - Federazione Russa 361
VN - Vietnam 344
HK - Hong Kong 313
UA - Ucraina 273
DE - Germania 209
FI - Finlandia 196
KR - Corea 98
GB - Regno Unito 93
FR - Francia 90
CA - Canada 44
PL - Polonia 36
AT - Austria 29
IN - India 29
AR - Argentina 25
MX - Messico 24
CH - Svizzera 23
BD - Bangladesh 22
ZA - Sudafrica 20
JP - Giappone 18
NL - Olanda 18
TR - Turchia 17
RO - Romania 13
ID - Indonesia 12
BE - Belgio 9
CZ - Repubblica Ceca 9
ES - Italia 8
GR - Grecia 8
IQ - Iraq 8
UZ - Uzbekistan 8
CO - Colombia 7
LT - Lituania 7
CL - Cile 6
EC - Ecuador 6
LB - Libano 6
MA - Marocco 6
PK - Pakistan 6
PY - Paraguay 6
BG - Bulgaria 4
OM - Oman 4
SN - Senegal 4
VE - Venezuela 4
IL - Israele 3
KE - Kenya 3
SA - Arabia Saudita 3
AL - Albania 2
BO - Bolivia 2
EG - Egitto 2
GA - Gabon 2
GT - Guatemala 2
IR - Iran 2
KZ - Kazakistan 2
ML - Mali 2
NG - Nigeria 2
NP - Nepal 2
PE - Perù 2
PH - Filippine 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AO - Angola 1
AU - Australia 1
AZ - Azerbaigian 1
BH - Bahrain 1
BW - Botswana 1
CD - Congo 1
CR - Costa Rica 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GE - Georgia 1
GM - Gambi 1
GP - Guadalupe 1
HU - Ungheria 1
JM - Giamaica 1
JO - Giordania 1
KW - Kuwait 1
KY - Cayman, isole 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
ME - Montenegro 1
NE - Niger 1
PT - Portogallo 1
SR - Suriname 1
UY - Uruguay 1
ZM - Zambia 1
Totale 9.441
Salva come PNG Salva come JPEG
Città #
Singapore 711
Chandler 628
Dublin 598
San Mateo 345
Hong Kong 313
Boardman 225
Santa Clara 174
Dong Ket 169
Andover 146
Medford 145
Princeton 143
Ashburn 141
Jacksonville 134
Perugia 132
Altamura 129
Lawrence 123
Beijing 109
Ann Arbor 107
Seoul 98
Wilmington 98
Moscow 84
Munich 83
Ho Chi Minh City 64
Los Angeles 53
Saint Petersburg 45
Hanoi 43
São Paulo 43
New York 40
Helsinki 38
Norwalk 31
Piscataway 31
San Paolo di Civitate 28
Brooklyn 24
Warsaw 22
Des Moines 21
Turku 19
Tokyo 18
Frankfurt am Main 17
Rio de Janeiro 17
Chicago 16
Redwood City 16
Boston 15
Falls Church 14
Johannesburg 14
Nuremberg 14
Denver 13
Mexico City 13
Woodbridge 13
Bucharest 12
London 12
Montreal 12
Poplar 12
The Dalles 12
Curitiba 11
Lausanne 11
San Francisco 11
Houston 10
Toronto 10
Vienna 10
Brussels 9
Dearborn 9
Guangzhou 9
Stockholm 9
Chennai 8
Da Nang 8
Den Haag 8
Falkenstein 8
Phoenix 8
Tianjin 8
Atlanta 7
Auburn Hills 7
Biên Hòa 7
Dallas 7
Orem 7
Santo André 7
Shanghai 7
Belo Horizonte 6
Dhaka 6
Haiphong 6
Lappeenranta 6
Manchester 6
Salvador 6
Seattle 6
Simi Valley 6
Amsterdam 5
Campinas 5
Campo Grande 5
Goiânia 5
Istanbul 5
Mumbai 5
Nanjing 5
Osasco 5
Ottawa 5
Paris 5
Ankara 4
Arezzo 4
Brasília 4
Calgary 4
Can Tho 4
Cape Town 4
Totale 5.895
Salva come PNG Salva come JPEG
Nome #
CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study 130
Afatinib In Egfr Mutant Non-small-cell Lung Cancer Patients With Acquired Resistance To Reversible Egfr-tkis 121
Significato prognostico dell’espressione immunoistochimica di Insulin like growth facor receptor 1 (IGFR-1) ed epidermal growth factor receptor (EGFR) nei carcinomi non a piccole cellule del polmone (NSCLC). 115
Prognostic Role of Erbb Family Receptors, Myc and Mitogen-activated Protein Kinase (mapk) In Patients With Early-stage Non Small-cell Lung Cancer 113
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: A combined methodology of gene expression profiling and computational gene network analysis 110
Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer 110
P-126 * PROGNOSTIC SIGNIFICANCE OF MYC AND HUMAN TELOMERASE GENE AMPLIFICATION IN SURGICALLY TREATED EARLY STAGE NON-SMALL CELL LUNG CANCER 107
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer 104
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series 103
Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. 100
Tumorlets, multicentric carcinoids, lymph-nodal metastases, and long-term behavior in bronchial carcinoids 95
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer 95
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease 95
An approach for optimally extending mathematical models of signaling networks using omics data 93
A machine learning approach applied to Reverse Phase Protein Microarray data for pathways activation mapping of KRAS wild type and mutated adenocarcinomas of the lung 93
Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors. 92
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer 92
A Hybrid Model of Nucleotide Excision Repair in Neoplastic diseases and in vitro Experiments 91
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. 91
Non-coding RNAs in lung cancer 90
Combined chemotherapeutic and radiotherapeutic treatment of limited pulmonary microcytoma 89
Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment 89
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 89
Acute myeloblastic leukemia after adjuvant chemo¬therapy with melphalan in breast cancer. Case report with cytogenetic analysis. 88
Phase II study of weekly paclitaxel and trastuzumab in anthracycline and taxane pretreated patients with HER2 overexpressing metatastatic breast cancer 87
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free servival in resected non-small-cell lung cancer patients. 86
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial 85
Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational Oncology 84
Conservative surgery and quality of life in a young patient with synchronous bilateral embryonal carcinoma. 83
A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. 82
KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts) 82
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort 82
A prospective study on survival in cancer patients with and without venous thromboembolism. 82
Espressione dei recettori HER nei carcinomi non a piccole cellule del polmone 81
Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one? 81
Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC). 79
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 79
Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study 79
Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non-Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. 79
Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors 78
Pathway Activation Mapping of Kras Wild Type and Mutated Adenocarcinomas of the Lung: New Implications For Patient Stratification For Map Kinase Pathway Inhibition 78
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial 78
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients 78
Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment 77
ALK Rearrangement Testing by FISH Analysis in Non-Small-Cell Lung Cancer Patients Results of the First Italian External Quality Assurance Scheme 77
EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients. 76
Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer Safety of Avastin in Lung trial (MO19390) 76
Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer 75
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study 75
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 75
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. 74
Dynamic network topologies analysis in proteomics data of NSCLC cell lines using a new pipeline based on machine learning tools 73
Carcinomi mammari “triple negative”: studio dei fattori prognostici e predittivi 72
MYC and Human Telomerase Gene (TERC) Copy Number Gain in Early-stage Non-small Cell Lung Cancer 72
Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational Oncology (vol 30, pg 142, 2012) 72
Targeting EGFR and ALK in NSCLC: current evidence and future perspective 72
Carcinomi mammari "triple negative": studio dei fattori prognostici e predittivi. 71
Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. 71
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. 70
High coexpression of both insulin-like growth factor receptor 1 (igfr-1) and epidermal growth factor receptor (egfr) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients 70
PD-L1 quantification across tumor types using the reverse phase protein microarray: Implications for precision medicine 70
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 69
Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors 68
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM) 68
Long-term survival and prognostic factors in neuroendocrine tumors: Results from a large multicenter study 67
Mutational analysis of KRAS, BRAF, and p53 genes in borderline and malignant epithelial ovarian tumors. 66
Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: A case report 66
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 66
ERCC1 expression in triple negative breast carcinoma: the paradox revisited. 65
Microinvasive breast cancer: clinical pathological characteristics and treatment. Experience from two institutions 65
Systems biology in personalized medicine in oncology: A case study in non-small cell lung cancer 65
An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy 65
Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection? 65
Perspectives of Novel Imaging Techniques for Staging, Therapy Response Assessment, and Monitoring of Surveillance in Lung Cancer Summary of the Dresden 2013 Post WCLC-IASLC State-of-the-Art Imaging Workshop 64
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up 64
Lack of Accuracy of Circulating Chromogranin A in the Preoperative Diagnosis of Lung Neuroendocrine Tumors 63
Clinical significances of ErbB family receptors, Myc, and mitogen-activated protein kinase (MAPK) in patients with early-stage non-small cell lung cancer. 63
Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology 63
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 61
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study 61
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice 61
Carcinomi mammari “tripli negativi”: significato biologico e prognostico dell’espressione di ERCC1. 60
Role of Expression Levels of Fabp3, H19, Tfpi2, Ark1b1 Cyp3a5, Scgb3a2 Genes In Adenocarcinoma Stage I Patients. 60
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype 60
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Non-Small Cell Lung Cancer Patients 59
Significato prognostico dell'espressione immunoistochimica di insulin like growth factor receptor 1 (IGFR-1) ed epidermal growth factor receptor (EGFR) nei carcinomi non a piccole cellule del polmone (NSCLC). 58
ERCC1 and RRM1 mRNA expression in resected patients with non-small-cell-lung-cancer (NSCLC). (A study of the Perugia multidisciplinary team for thoracic tumors) 58
Effect of genetic polymorphisms (GP) on toxicity and survival in early breast cancer (EBC) patients (PTS) treated with adjuvant chemotherapy (CT) 58
Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation. 57
Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases 57
Mir-99a/let7c/mir-125b Signature To Predict Sensitivity To Anti-egfr Monoclonal Antibodies In Metastatic Colorectal Cancer (mcrc) 56
Frequency and clinical correlations of epidermal growth factor receptor (EGFR) mutations in a large cohort of Italian non-small cell lung cancer (NSCLC) patients (pts) within the EGFR FASTnet program. 55
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 55
Robustness of complex feedback systems: application to oncological biochemical networks 54
Impact of Kras Codon Sub-types In A Phase Ii Second-line Trial In Kras-mutant Advanced Non-small Cell Lung Cancer (nsclc) of Selumetinib Plus Docetaxel Versus Docetaxel Alone 54
First-Line Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer 54
Italian Multicenter Phase III Randomized Study of Cisplatin-Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM Trial 54
Antigen-Presenting Signaling Events in the Tumor Ecology Associate with Response to Anti-PD-1 Treatment in Lung Cancer 53
Emerging drugs for small cell lung cancer - an update 53
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis 53
Totale 7.619
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.998
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.998
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021527 0 0 0 0 0 79 48 5 99 41 64 191
2021/20221.152 29 237 12 75 19 11 7 446 14 12 119 171
2022/20232.061 149 394 16 180 157 206 0 96 772 1 69 21
2023/2024630 44 75 51 16 6 1 122 7 47 29 112 120
2024/20251.735 43 168 100 47 270 48 32 122 351 114 236 204
2025/20262.169 296 316 227 551 511 268 0 0 0 0 0 0
Totale 9.727